Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
about
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesSupersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope SpikeNatively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding siteGlycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodiesComputational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity dataMolecular dynamics analysis of antibody recognition and escape by human H1N1 influenza hemagglutinin.HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residuesA human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesThe genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationThe glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicityPartial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.HIV-1 envelope glycan moieties modulate HIV-1 transmission.Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systemsEvidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.Polyreactivity and autoreactivity among HIV-1 antibodies.A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry.Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesMechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls.Enhanced HIV-1 neutralization by antibody heteroligation
P2860
Q21558777-758133F7-B602-45F4-A2F5-51216835C9FCQ27319450-9A1D0833-B6E7-4067-924A-C9B33C56227AQ27674878-2FCA402A-6A5D-4598-BED6-6B6193163F24Q27678306-23F965E9-D012-4D05-9845-6B357D7DED92Q27678312-80D2A128-E1A4-42B2-B004-121E6147684FQ27683540-8B464C8F-73B0-4C72-9F06-7C1345BA1B3CQ27728037-7C1376CB-EDFE-4CD9-9979-04DA8F700E75Q28263932-1CBAA0AC-6B13-4C5E-8241-BAB1D4B35BDFQ28535583-B67B1948-14B2-4127-BCBC-FEB4E6CD5574Q30375271-56EB6D2B-E971-46AD-A766-62CA29ADA344Q30393763-8EDE2225-18FC-4D54-9380-9664A3B7A878Q30490942-39F5EA64-364F-467F-B453-5238A8C5C415Q30644992-E46CA8A7-48E3-4E9F-BB4A-9C2F0F9A08DCQ31132248-9D235AEA-6235-4553-A66C-DBFA71B36048Q33683203-6BB37377-14F5-4E38-8EA4-902E93E5B45BQ33839456-6EA162A7-DB98-4426-8797-6DD4FBF093CDQ33912373-3E0BD70A-E743-4C00-81A7-823AF3151E00Q33946158-4667371A-87BB-4317-B925-61F06D99E4A5Q33999756-01E4F315-9C24-4F6A-A7CF-78B81608A24EQ34016211-447B700E-C17A-44A4-8990-19A4AF6F61E6Q34175370-DA5607CA-20BE-498C-AF06-426976AE8DA5Q34285680-782871E6-D34A-416B-926B-9007D2C9897EQ34299053-4B8606BB-6AFB-4384-B22E-09EE4B432E6AQ34396095-08DA10BB-99CE-444F-BEBE-FC4C0B4125B1Q34540645-EB045901-4EAA-4164-9518-80DF6AB9C0ECQ34551010-F143E814-5943-491B-83E9-ED49FF8AB288Q34555891-4136ED51-2F94-4230-8BD2-405EF76F8725Q34595009-F5C37420-EF64-410B-9AD8-83047CE37F85Q34637663-D59B2B25-EA44-409D-9711-B2923502DF0AQ34819651-CD875F75-7B40-4A73-A2A6-DE422477C589Q34992787-1C817BF4-C585-4ED7-8A3E-58D0B792F883Q35063075-4557EB7D-2F14-4B84-9BE7-1E15D51D5472Q35076987-44341703-BA50-454D-82E3-A113906A47A5Q35092308-F9BC38DE-BF49-4F36-8AFE-6D024C62A43CQ35116581-44A47A3C-E464-406D-9004-14CE666DB981Q35140429-BC60C3FB-65C9-4BD2-B38E-98FF427FFD91Q35167400-C81D7928-0563-4D4B-B7E1-7C62967A464CQ35192782-AF41F618-5E00-4D3F-87CC-D3EC16EEA3D5Q35336374-9B51FBC3-DB55-4A67-99A9-747F19E09C73Q35735385-D8ECC234-F679-4FC3-830D-0A4A091B47A3
P2860
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Role of complex carbohydrates ...... nce to antibody neutralization
@en
Role of complex carbohydrates ...... ce to antibody neutralization.
@nl
type
label
Role of complex carbohydrates ...... nce to antibody neutralization
@en
Role of complex carbohydrates ...... ce to antibody neutralization.
@nl
prefLabel
Role of complex carbohydrates ...... nce to antibody neutralization
@en
Role of complex carbohydrates ...... ce to antibody neutralization.
@nl
P2093
P2860
P356
P1433
P1476
Role of complex carbohydrates ...... nce to antibody neutralization
@en
P2093
Dirk Eggink
Emma T Crooks
James M Binley
Keiko Osawa
Rogier W Sanders
William R Schief
Yih-En Andrew Ban
P2860
P304
P356
10.1128/JVI.00105-10
P407
P577
2010-03-24T00:00:00Z